Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-6.14 Insider Own0.10% Shs Outstand400.44M Perf Week-1.16%
Market Cap90.22B Forward P/E13.39 EPS next Y16.83 Insider Trans0.00% Shs Float395.30M Perf Month-5.61%
Income-2422.60M PEG- EPS next Q3.61 Inst Own87.50% Short Float2.34% Perf Quarter-13.43%
Sales15.37B P/S5.87 EPS this Y23.00% Inst Trans0.03% Short Ratio2.82 Perf Half Y2.37%
Book/sh181.28 P/B1.24 EPS next Y20.72% ROA3.00% Target Price299.29 Perf Year-17.04%
Cash/sh1.27 P/C178.08 EPS next 5Y13.27% ROE5.70% 52W Range195.50 - 322.68 Perf YTD-27.91%
Dividend- P/FCF20.46 EPS past 5Y-50.40% ROI-1.30% 52W High-30.18% Beta1.03
Dividend %- Quick Ratio0.90 Sales past 5Y33.40% Gross Margin78.70% 52W Low15.24% ATR5.24
Employees31200 Current Ratio1.00 Sales Q/Q1.50% Oper. Margin-16.50% RSI (14)39.93 Volatility1.70% 2.31%
OptionableYes Debt/Eq0.56 EPS Q/Q9.70% Profit Margin27.00% Rel Volume0.53 Prev Close225.93
ShortableYes LT Debt/Eq0.52 EarningsNov 02 BMO Payout0.00% Avg Volume3.28M Price225.29
Recom1.90 SMA20-3.31% SMA50-5.77% SMA200-9.99% Volume1,747,838 Change-0.28%
Oct-11-16Reiterated Mizuho Buy $305 → $299
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Apr-07-16Downgrade Susquehanna Positive → Neutral
Apr-06-16Downgrade Mizuho Buy → Neutral $330 → $250
Mar-31-16Reiterated Canaccord Genuity Buy $340 → $320
Feb-23-16Reiterated Mizuho Buy $354 → $330
Feb-23-16Reiterated Deutsche Bank Buy $308 → $339
Feb-19-16Initiated Wells Fargo Outperform
Oct-25-16 10:03AM  Hedge Funds Are Cashing Out Of These Stocks As Investors Yank Capital at Insider Monkey
08:30AM  KYBELLA® (deoxycholic acid) injection 10 mg/mL Puts "Profiles in Focus" With Expert Panel And New Direct-To-Consumer Campaign PR Newswire
07:46AM  Allergan Successfully Completes Vitae Tender Offer PR Newswire
Oct-24-16 06:37PM  Why Jim Cramer says the hottest theme on Wall Street is your selfie stick at CNBC
06:25PM  Cramer says the hottest theme on Wall Street is thanks to...
03:34PM  TIMEWARNER-M&A/AT&T-LOANS-Market welcomes AT&T's $40 bln Time Warner loan Reuters
01:09PM  Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says at
11:30AM  Biosimilars May Pose a Threat to Roches Herceptin
08:05AM  Allergan to Present New Data from its Anti-Infectives Portfolio at IDWeek 2016 in New Orleans PR Newswire
Oct-22-16 12:01AM  [$$] Allergan's Upside: 20%-30% at
Oct-21-16 04:03PM  Gilead NASH Drug 'Active And Promising,' But Lagging Intercept
11:45AM  Invest in Allergan on Weakness, Analysts Say
10:06AM  Allergan's Nocturia Drug Gets FDA Advisory Committee's Nod
08:28AM  Pharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved
07:45AM  Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma at 24/7 Wall St.
Oct-20-16 02:35PM  FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray) PR Newswire
12:40PM  Gilead Sciences: 'Far From Compelling' at
10:04AM  Eli Lilly and Co.s 3Q16 Estimates: Oncology Franchise
Oct-19-16 04:11PM  FDA panel backs Allergan's drug for frequent nightly urination Reuters
11:03AM  Wellesley clinical trial software startup raises $5M at
10:06AM  Eli Lilly and Co.s 3Q16 Estimates: Endocrine Franchise
09:00AM  Allergan (AGN) Brings Juvederm Voluma XC to U.S. Market
08:06AM  Eli Lillys 3Q16 Estimates: Expect Revenue Growth!
08:00AM  Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira PR Newswire
Oct-18-16 04:04PM  Options Insight: How to Play Allergan
04:04PM  Options Insight: How to Play Allergan at Bloomberg
09:00AM  JUVÉDERM VOLBELLA® XC Now Available To Doctors And Patients In The U.S. PR Newswire
Oct-17-16 11:04AM  Johnson & Johnsons Expected Profitability in 3Q16
10:35AM  FDA staff flag concerns about Allergan's urinary drug Reuters
09:22AM  FDA staff flags concerns about Allergan, Serenity Pharma urinary drug Reuters
09:14AM  Allergan (AGN) Gains Rights to RTGel from UroGen Pharma
08:57AM  Allergan's Belkyra Gets Swedish Approval for Double Chin
08:04AM  This Space Presents a Market Opportunity for Valeant
08:01AM  Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City PR Newswire
08:00AM  Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan's Proposed Acquisition of Vitae PR Newswire
06:00AM  Making Sense of Merger-Arbitrage Funds at Morningstar
Oct-16-16 08:01AM  Allergan Demonstrates Ongoing Commitment to Irritable Bowel Syndrome (IBS) with Development of IBS CounSEL PR Newswire
Oct-14-16 04:15PM  Shire Routs Incumbent Allergan In Booming Dry-Eye Market: RBC
02:30PM  No, Virginia, the M&A market has not gone into a death spiral
08:00AM  Allergan Demonstrates Continued Commitment to Irritable Bowel Syndrome with Diarrhea Management with Two Poster Presentations at ACG 2016 PR Newswire
07:00AM  UroGen Pharma Announces Agreement to License RTGel for Use with Neurotoxins to Allergan GlobeNewswire
Oct-13-16 07:05PM  [$$] US modifies plans to crack down on inversions at Financial Times
05:32PM  Treasury takes its latest step to keep corporate taxes in the US at CNBC
04:29PM  Pfizer Will Likely Overpay For M&A Post-Allergan Breakup Flop: Jeffries
04:15PM  Allergan to Host Third Quarter 2016 Earnings Conference Call and Webcast PR Newswire
03:00PM  Keep Calm and Focus on What Is Significant
02:30PM  Allergan Gets Priority Review for Avycaz Label Expansion
09:24AM  ETFs with exposure to Allergan Plc : October 13, 2016
09:01AM  Allergan Partners with SonarMD® to Develop Innovative IBS-D Patient Engagement Platform for Better Identification and Care of IBS-D Patients PR Newswire
08:04AM  In Depth Review of Gilead Sciences NASH Pipeline Opportunities
07:00AM  Allergan's BELKYRA® (Deoxycholic Acid) Receives Marketing Authorisation In Sweden For The Treatment Of Moderate To Severe Fullness Under The Chin (Double Chin) PR Newswire
Oct-12-16 06:57PM  [$$] Eye research closes in on blockbuster drugs at Financial Times
06:57PM  [$$] Drugmakers respond to growing need for eye treatments at Financial Times
04:15PM  Controversy Over Allergan's 500% Premium for Tobira Looks Overdone
02:33PM  Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD
10:27AM  US stocks steady as oil prices fall; bond yields surge
Oct-11-16 04:18PM  Allergan Challenges Intercept With Tobira NASH Drug
10:01AM  Allergan Launches #ActuallySheCan(SM) Mentorship, Sharing Inspirational Portraits And Interviews Of Women In Entertainment, Sports And Business PR Newswire
08:01AM  FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam) PR Newswire
01:42AM  Nestle appoints new CEO for skin health business
Oct-10-16 04:24PM  S&P 500s triangle chart pattern warns of a big selloff, analyst says at MarketWatch
09:20AM  Repros' Secondary Hypogonadism Drug under Review in EU
08:05AM  Allergan to Showcase Novel and Expanding Eye Care Portfolio with New Data Presentations at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago PR Newswire
Oct-09-16 07:05AM  3 Tax Loopholes Hillary Clinton Wants to Close at Motley Fool
Oct-08-16 01:53AM  [$$] Baxalta Could Boost Shire Shares More Than 25% at
Oct-07-16 09:57AM  5 Stock Picks Ahead of World Mental Health Day
08:05AM  Allergan and the Dystonia Medical Research Foundation Continue Longstanding Partnership PR Newswire
Oct-06-16 06:06PM  John Paulson's Health Care Stocks Drop Far Below Sector Return
04:33PM  ALLERGAN PLC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S
04:28PM  Pfizer to seek more modern Manhattan headquarters Reuters
08:12AM  Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good
06:10AM  [$$] Allergan steps out of Pfizer ashes with $7bn of deals at Financial Times
Oct-05-16 03:03PM  Teva Divests More Assets to Win EC Approval for Allergan Generics Deal
12:29PM  [$$] Teva Sells Actavis Generics European Assets to Accord Healthcare at The Wall Street Journal
12:04PM  Teva to sell Allergan's generics business in UK, Ireland for $769 mln Reuters
09:30AM  The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals
09:22AM  [$$] Indian drugmaker buys Actavis' UK and Ireland business at Financial Times
09:00AM  New Study Showcases Economic Impact of Allergan's Operations on New Jersey Economy PR Newswire
08:04AM  Allergan Enters the Attractive NASH Market
08:04AM  AstraZeneca Heart Drug Brilinta Fails a Study; Shares Down
Oct-04-16 05:59PM  Teva Boosts Generic Business with Allergan Anda Takeover
11:04AM  Understanding Gilead Sciences NASH Pipeline
08:55AM  Allergan Buys Rights to AstraZeneca's Crohn's Disease Drug
08:50AM  Blog Coverage AstraZeneca Enters into an Agreement with Allergan
08:42AM  5 FDA Decisions to Watch Out for in October 2016
07:00AM  Financial Services: Berkshire Is Bigger Than Buffett at Morningstar
Oct-03-16 03:27PM  3 things to know about Janus Capitals planned merger with Henderson at MarketWatch
11:33AM  Why Allergan, eBay, Dynavax, KBR, and More Are Trending at Insider Monkey
11:05AM  $1.5B deal: AstraZeneca licenses experimental Crohn's disease drug to Allergan at
10:45AM  Botox-maker Allergan just struck another billion-dollar deal
10:31AM  Allergan's New Products And Robust R&D Pipeline Support A Positive Long-Term View
10:13AM  [$$] Allergan to buy bowel disease drug from AstraZeneca at Financial Times
10:06AM  Recent Corporate and R&D Progress for Merck & Co.
08:39AM  6 Best Performing Drug Stocks of September
07:00AM  Stock Market Outlook: A Little Too Buoyant? at Morningstar
04:06AM  European Stock Markets Rise; Pound Falls on Brexit Countdown, Henderson up on Janus Merger
02:21AM  AstraZeneca licenses inflammatory disease candidate to Allergan Reuters
02:00AM  Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program PR Newswire
Sep-30-16 04:39PM  Depomed fends off Allergan's attempt at generic painkiller at MarketWatch
03:04PM  Cempra Gets More Good News
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians' offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.